JAN 21, 2017 09:18 AM PST

The Cues that Tell Pancreatic Cancer to Steal

WRITTEN BY: Xuan Pham

Acting like cunning thieves in the night, pancreatic cancer can hack into their microenvironment to selfishly steal the essential nutrients for its own survival. A new study highlights the mechanisms behind this process, and points to a promising drug candidate that may prevent theft of the nutrients.

Tumor (green), stromal cells (red) | Image: Salk Institute"Pancreatic cancer is a deadly disease and is very understudied when it comes to how it communicates with the microenvironment," said Ronald Evans, director of Salk's Gene Expression Laboratory, and the study’s senior author. "Our findings open up a lot of avenues for future study."

Indeed, scientists have shown that the stromal microenvironment, made up of fat and connective cells that provide structural support for tissues and organs, plays a big role in supporting tumor growth. But exactly how this happens remained a complex mystery.

To understand how tumors hack into this microenvironment, researchers at the Salk Institute replicated this biological process with and without signaling chemicals from the pancreatic stroma. "We worked out a culture system so that we could grow human pancreatic cells in a three-dimensional system in both the presence and absense of stromal signals," said Mara Sherman, the study’s first author.

The team showed that tumors relied on stromal molecules to mobilize their entire metabolic process. In essence, signaling molecules trigger the tumors to accelerate their growth and overall metabolism. At the epigenetic level, the tumors had increased histone acetylation at transcriptionally enhanced genes, which suggests a deeper level of genetic alteration.

"The tumor is essentially hacking into that stromal microenvironment and grabbing what it needs to up its metabolism," said Michael Downes, one of the study’s co-authors.

The Salk team hypothesized that changes at the epigenetic level implicates the pancreatic cancer epigenome as a therapeutic target. That is, blocking the signals at the epigenetic level may prevent the tumor cells from hacking into its microenvironment.

To test this hypothesis, the team administered an epigenetic inhibitor known as JQ1 into their cancer models. In cells, the drug blocked the stromal signals and reversed the genetic changes associated with increased metabolism. In a mouse model, the drug slowed tumor progression significantly.

The team plans to follow-up this pathway with JQ1 and other inhibitors to understand whether it will be effective in humans. Of note, pancreatic cancer is notorious for its lethality. Only about 25 percent of patients survive past the one-year mark from diagnosis. Thus, any insight that can be translated into drug therapies offers huge hope for patients. 

Additional sources: Salk Institute 

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
JUN 07, 2018
Clinical & Molecular DX
JUN 07, 2018
Digital Screening Vital for Detecting Breast Cancer
A combination of two digital techniques could be the best way to diagnose breast cancer. In a new study, scientists show how combining a technique called t...
JUN 27, 2018
Infographics
JUN 27, 2018
The Role of Biomarkers In Modern Medicine
A biomarker (short for biological marker) is a measurable indicator of some biological state or condition. The biomarker can be measured objectively and consistently. Biomarkers play signific...
JUL 24, 2018
Cancer
JUL 24, 2018
FDA Approves New Drug for Refractory/Relapsed AML
A new drug and new drug class have been approved by the FDA for relapsed or refractory AML patients with an IDH1 mutation. The new drug offers options for patients....
JUL 31, 2018
Cancer
JUL 31, 2018
Protein Regulation of DNA Replication in Cancer Cells - A New Early Target for Broad Therapeutics?
DNA replication is a carefully regulated process in each cell of the body. Researchers are looking at the mechanism of DNA replication and associated proteins as a therapy target in cancer...
AUG 14, 2018
Cancer
AUG 14, 2018
Using Arsenic to Enhance Cancer Therapies Beyond Leukemia
An already existing combination of arsenic and all-trans retinoic acid is found to inhibit a key signaling pathway that exerts broad effect on oncogenic processes for some solid tumors....
AUG 28, 2018
Drug Discovery
AUG 28, 2018
Combination Therapy for Advanced Melonoma
According to a research study led by UCLA, a bacteria-like agent used in combination with an immunotherapeutic drug may help patients survive longer with a...
Loading Comments...